Trial Title:
A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors
NCT ID:
NCT06329206
Condition:
Advanced Solid Tumors
Conditions: Official terms:
Neoplasms
Study type:
Interventional
Study phase:
Phase 1
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
GH2616 Tablets
Description:
GH2616 tablets will be given orally
Arm group label:
GH2616 GROUP
Summary:
This is a Phase Ia/Ib, dose escalation and dose expansion study to evaluate the safety,
tolerability, PK, pharmacodynamics (PD) and preliminary efficacy of GH2616 Tablet in
subjects with advanced solid tumors. It includes two parts: the dose escalation study
(Phase Ia) and the dose expansion study (Phase Ib).
Detailed description:
Phase Ia: Dose Escalation Study This is a Phase Ia, open-label, multi-center, dose
escalation study, aiming to investigate the safety, tolerability, PK, PD and preliminary
anti-tumor activity of GH2616 Tablet in subjects with advanced solid tumors.
• Dose Escalation Phase This study will consist of 8, sequential, ascending-dose cohorts
(A1~ A8) and utilize a "3+3" dose escalation design.
Phase Ib: Dose Expansion Study The Phase Ib part is an open-label, multi-center, dose
expansion study, aiming to further evaluate the safety, tolerability, PK, PD, and
preliminary anti-tumor activity of GH2616 Tablet in subjects with advanced solid tumors
harboring TP53 mutation and WGD+ at the RDEs.
Phase Ib study will consist of 2 to 3 dose level cohorts (B1 ~ B3) of RDEs identified by
the safety, tolerability, PK/PD characteristics, and preliminary efficacy data obtained
from Phase Ia study.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Subjects must meet all of the following inclusion criteria to be eligible for
participation in this study:
1. Men or women ≥18 years old.
2. The following two points are evaluated by the Investigator and are deemed
suitable to participate in the study: a. The subject fully understands the
requirements of the study and voluntarily signs the written informed consent;
b. Be able to comply with the medication requirements of the study and all
study related procedures and evaluations.
3. Meeting the requirements of tumor types shown below:
Phase Ia Study:
Subjects with a histological or cytological diagnosis of recurrent or
metastatic advanced solid tumors who have failed or are intolerant to standard
treatment, or have no standard therapy. The specific tumor types include but
not limited to high-grade serous ovarian cancer (HGSOC), uterine carcinosarcoma
(UCS), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC),
triple-negative breast cancer (TNBC), bladder urothelial carcinoma (BLCA),
colorectal cancer (CRC), etc.
Phase Ib study:
Dose expansion study (Phase Ib): Subjects with a histological or cytological
diagnosis of recurrent or metastatic advanced solid tumors harboring TP53
mutation and WGD+ who have failed or are intolerant to standard treatment, or
have no standard therapy.
The specific tumor types include but not limited to high-grade serous ovarian
cancer (HGSOC), uterine carcinosarcoma (UCS), lung adenocarcinoma (LUAD), lung
squamous cell carcinoma (LUSC), triple-negative breast cancer (TNBC), bladder
urothelial carcinoma (BLCA), colorectal cancer (CRC), etc.. Note: The specific
tumor types/basket design with specific gene(s) will be determined by the
principal Investigator and the Sponsor based on the Phase Ia study results.
4. Survival expectations are ≥ 12 weeks.
5. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 (Appendix
1).
6. Subjects with advanced solid tumors have at least one evaluable lesion
according to RECIST 1.1 (Appendix 2).
7. Subjects with adequate organ function at the time of screening (requiring no
blood transfusion, no use of hematopoietic stimulating factor or human albumin
within 14 days prior to screening), specifically defined as:
1. Blood routine: Absolute neutrophil count (ANC) ≥ 1.5×109/L; Platelet count
(PLT) ≥100×109/L; Hemoglobin (HGB) ≥ 90 g/L (9 g/dL);
2. Liver function: Serum Total bilirubin (TBIL) ≤ 1.5 Upper limit of normal
value (ULN), and serum TBIL≤ 3×ULN in patients with liver metastasis or
confirmed Gilbert syndrome. Alanine aminotransferase (ALT) and Aspartate
transferase (AST) ≤ 2.5×ULN in subjects without liver metastasis; ALT or
AST≤ 5×ULN in subjects with liver metastasis;
3. Renal function: estimated creatinine clearance (CLcr) ≥ 60 mL/min as
calculated using Cockcroft-Gault formula (Appendix 3);
4. Coagulation function: Activated Partial thromboplastin Time (APTT) and
international normalized ratio (INR) ≤ 1.5×ULN (or within target range if
on anticoagulation therapy);
5. Cardiac function: Echocardiography (ECHO) shows left ventricular ejection
fraction (LVEF) > 50%.
8. Serum pregnancy test (for female of childbearing potential) negative within 7
days prior to first dosing of study treatment. Male and female subjects of
childbearing potential must agree to use effective methods of contraception
throughout the study and for 3 months (male) or 6 months (female) after the
last dose of the investigational product. A subject is of childbearing
potential if, in the opinion of the Investigator, he/she is biologically
capable of having children and is sexually active.
Exclusion Criteria:
- In Phase Ia and Ib studies, subjects will be excluded if they meet any of the
following criteria:
1. Has received chemotherapy within 21 days prior to the first administration of
GH2616 Tablet or has received radiation therapy, biologic therapy, endocrine
therapy, targeted therapy, immunotherapy, or other anti-tumor drug treatments
within 28 days prior to the first administration of GH2616 Tablet, or other
anti-tumor drugs or treatments within the following interval before the first
administration of GH2616 Tablet: Nitrosoureas or mitomycin C within 6 weeks
prior to the first administration of the investigational drug. Oral
fluoropyrimidines, small molecule targeted therapies, and Chinese herbal
medicines with indications for anti-tumor within 14 days prior to the first
administration of the investigational drug. Local palliative radiation therapy
within 14 days prior to the first administration of the investigational drug.
2. Has received other investigational drugs or treatments not yet approved for
marketing within 28 days prior to the first administration.
3. Acute toxic effects of prior anti-tumor therapy have not recovered to
clinically significant NCI-CTCAE V5.0 grade ≤ 1 toxicity or baseline specified
in the inclusion criteria within 28 days prior to the first administration of
GH2616 Tablet (excluding toxicities such as alopecia and fatigue that the
Investigator deems to have no safety risk).
4. At rest, the average Corrected QT interval (QTc, Fridericia's correction
formula used) obtained by 12-lead Electrocardiograph (ECG) examination is > 450
ms for males or 470 ms for females (confirmed by repeated examinations). A
variety of clinically significant arrhythmia, conduction, and resting ECG
abnormalities, such as complete left bundle branch block, degree III, degree
II, PR interval >250 ms. Various factors that may increase the risk of
prolonged QTc or arrhythmia events, such as heart failure, hypokalemia,
congenital long QT syndrome, a family history of long QT syndrome in a direct
family member or sudden unexplained death before age 40, and use of any
medications known to prolong QT intervals.
5. Has evidence of infectious diseases:
1. Active hepatitis B (hepatitis B surface antigen (HbsAg) positive and
hepatitis B virus deoxyribonucleic acid (HBV-DNA) > 500 IU/ml or 1000
cps/ml or lower limit of detection at the study site [only if lower limit
of detection at the study site is higher than 500 IU/ml or 1000 cps/ml]),
antiviral therapy other than interferon is allowed; active hepatitis C
(subjects with hepatitis C virus (HCV) antibody positive but hepatitis C
virus ribonucleic acid (HCVRNA) < lower limit of detection at the study
site are allowed to be enrolled);
2. HIV infected patients (HIV 1/2 antibody positive detected by
antigen/antibody test); Considering that HIV infections can be chronically
managed, expanding cancer clinical trial eligibility to be more inclusive
of patients with HIV infections is justified in many cases, and may
accelerate the development of effective therapies in cancer patients with
these chronic infections. Therefore, well-controlled HIV patients who have
been on established antiretroviral therapy (ART) for at least four weeks
and have an HIV viral load less than 400 copies/mL prior to enrollment
should be included. Note: patients who are using ART drugs that are
prohibited or cautious concomitant medications specified in the protocol
(e.g. strong inhibitors or strong inducers of P-gp) could be switched to
an alternate effective ART regimen (with minimal drug-drug interaction
potential) before study participation or should be excluded from the study
if their regimen cannot be altered.
3. Known active syphilis infection.
6. Has symptomatic or active central nervous system (CNS) metastases. Treated or
untreated asymptomatic patients with CNS lesions are eligible only if all of
the following criteria are met:
1. Presence of measurable lesions outside the CNS as determined by RECIST
1.1.
2. No history of intracranial or spinal hemorrhage.
3. No stereotactic radiation therapy or whole brain radiation therapy or
neurosurgical resection within 28 days prior to initiation of study
treatment.
4. No continuous use of corticosteroids during CNS disease treatment period.
5. Metastases limited to the cerebellum or supratentorial region (i.e., no
metastases to the midbrain, pons, medulla, or spinal cord).
6. No evidence of intermediate progression between completion of CNSdirected
therapy (if given) and initiation of study treatment.
7. Concurrent diseases that have not been controlled, such as:
1. Severe infection, including but not limited to hospitalization due to
infection, bacteremia, or severe pneumonia complications, occurs within 28
days prior to initiation of study treatment; Or patients who received
therapeutic oral or intravenous antibiotics within 14 days prior to
starting study treatment; Subjects receiving prophylactic antibiotics for
needle biopsy can be included.
2. Heart failure consistent with New York Heart Association Grades ≥ II
within 6 months prior to initiation of study treatment.
3. Other malignancies (other than in situ cancers such as non-melanoma basal
cell carcinoma or squamous cell carcinoma of the skin, breast/cervical
carcinoma in situ, superficial bladder carcinoma that have received
radical treatment and no evidence of disease recurrence, etc.) within 5
years prior to initiation of treatment.
4. Current subjects with cancerous meningitis, spinal cord compression, etc..
5. Has a history of poorly controlled hypertension within 28 days prior to
initiation of study treatment, defined as systolic blood pressure ≥ 160
mmHg or diastolic blood pressure ≥ 100 mmHg, despite treatment with
multiple antihypertensive medications.
6. Any arterial thromboembolic event, including myocardial infarction,
unstable angina pectoris, cerebrovascular accident, or transient ischemic
attack, occurred within 6 months prior to initiation of study treatment.
7. Significant malnutrition, such as the need for intravenous nutrient
supplementation. Those who were stable for more than 28 days after
correction of malnutrition before treatment of first dose of
investigational product could be included.
8. Tumor invasion of surrounding important organs or blood vessels (such as
mediastinal great vessels, superior vena cava, trachea, esophagus, etc.),
or at risk of esophagotracheal fistula or esophagopleural fistula.
9. After endoesophageal or tracheal stent implantation.
10. Has a history of gastrointestinal perforation and/or fistula 6 months
prior to initiation of study treatment.
11. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring
repeated drainage (monthly or more frequent).
12. Uncontrolled tumor-related pain, or no stable pain regimen.
8. Allergic to GH2616 Tablet or its components.
9. Significant impairment of oral drug absorption, such as inability to swallow,
chronic diarrhea, and intestinal obstruction, etc..
10. Has severe lung disease or history, such as moderate to severe chronic
obstructive pulmonary disease (COPD), evidence of interstitial lung disease
(ILD)/pneumonitis on baseline imaging, history of ILD, drug-induced ILD, acute
or chronic infectious pneumonia, lung transplantation, etc..
11. Use of strong inhibitors or inducers of P-glycoprotein (P-gp) within 14 days or
5 halflives (whichever is longer) before the first administration (refer to
Appendix 5).
12. Use of sensitive narrow therapeutic index CYP3A4 substrate within 14 days or 5
halflives (whichever is longer) before the first administration (refer to
Appendix 4).
13. Pregnant or lactating women.
14. Known history of allogeneic organ transplantation and allogeneic hematopoietic
stem cell transplantation.
15. Has a major surgical procedure (craniotomy, thoracotomy, laparotomy, vascular
intervention) within 28 days prior to the first administration, or had an
unhealed wound, ulcer, or fracture. Note: For palliative care purposes, local
surgical treatment of isolated lesions is acceptable.
16. Has a clear history of mental disorder with ongoing treatment.
17. Has a treatment history of KIF18A inhibitor.
18. Subjects with POLE gene hotspot mutated, or hypermutator phenotype.
19. In the opinion of the Investigator, there are other factors that the subject is
unsuitable for participation in this clinical study.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Zhejiang Cancer Hospital
Address:
City:
Zhejiang
Country:
China
Status:
Recruiting
Contact:
Last name:
ZHENGBO SONG, DOCTORATE
Phone:
+8613857153345
Email:
zjccgcp_phase1@126.com
Start date:
March 20, 2024
Completion date:
September 1, 2026
Lead sponsor:
Agency:
Suzhou Genhouse Bio Co., Ltd.
Agency class:
Other
Collaborator:
Agency:
Zhejiang Cancer Hospital
Agency class:
Other
Collaborator:
Agency:
Henan Cancer Hospital
Agency class:
Other
Collaborator:
Agency:
Hubei Cancer Hospital
Agency class:
Other
Collaborator:
Agency:
The First Affiliated Hospital of Zhengzhou University
Agency class:
Other
Source:
Suzhou Genhouse Bio Co., Ltd.
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06329206